Retained Display News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The majority of oncogenic drivers are intracellular proteins, constraining their immunotherapeutic targeting to mutated peptides (neoantigens) presented by individual human leukocyte antigen (HLA) allotypes1. However, most cancers have a modest mutational burden that is insufficient for generating responses using neoantigen-based therapies2,3. Neuroblastoma is a paediatric cancer that harbours few mutations and is instead driven by epigenetically deregulated transcriptional networks4. Here we show that the neuroblastoma immunopeptidome is enriched with peptides derived from proteins essential ...

ENewsChannels NEWS: -- Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC's proprietary offering of MHC peptide targets for oncology with Myrio's revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer. :: News from eNewsChannels

New CAR T Approach Clears Brain Cancer Tumors in Preclinical Models Fluorescence labelling of distinct layers of the brain. Each color represents a different cell type within the cortex. [Maria Bergamasco, Walter and Eliza Institute of Medical Research] May 10, 2021 Fluorescence labelling of distinct layers of the brain. Each color represents a different cell type within the cortex. [Maria Bergamasco, Walter and Eliza Institute of Medical Research] Share Scientists in Australia report that they used chimeric antigen receptor (CAR) T cell therapy to clear brain cancer tumors in preclinical ...